Details of the Drug

General Information of Drug (ID: DMUWFD8)

Drug Name

Sacituzumab govitecan

Synonyms

hRS7-SN38; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; UNII-M9BYU8XDQ6; hRS 7SN38; Satralizumab linker; IMMU 132; IMMU-132; M9BYU8XDQ6; 1491917-83-9; sacituzumab-govitecan; DA64T2C2IO; CYSTEINYL CL2A-SN-38; SN-38 CYSTEINYL CONJUGATE; DTXSID401335985; EX-A4354; GOVITECAN CYSTEINYL CONJUGATE; F82944; 1535963-91-7; 1796566-95-4

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Urothelial carcinoma	2C92.0	Approved	[1]
Non-small-cell lung cancer	2C25	Phase 3	[2]

Affected Organisms

Humans and other mammals

ATC Code

L01FX17: Sacituzumab govitecan

L01FX: Other monoclonal antibodies and antibody drug conjugates

L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Antibody drug conjugate

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C76H104N12O24S
Canonical SMILES: CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SCC(C(=O)O)N)C2=NC9=C1C=C(C=C9)O
InChI: InChI=1S/C76H104N12O24S/c1-3-55-56-37-54(89)16-17-61(56)83-68-57(55)43-87-63(68)38-59-58(71(87)95)45-110-74(99)76(59,4-2)112-75(100)111-44-50-10-14-52(15-11-50)81-70(94)62(7-5-6-18-77)82-66(91)47-109-46-65(90)79-19-21-101-23-25-103-27-29-105-31-33-107-35-36-108-34-32-106-30-28-104-26-24-102-22-20-86-42-53(84-85-86)40-80-69(93)51-12-8-49(9-13-51)41-88-67(92)39-64(72(88)96)113-48-60(78)73(97)98/h10-11,14-17,37-38,42,49,51,60,62,64,89H,3-9,12-13,18-36,39-41,43-48,77-78H2,1-2H3,(H,79,90)(H,80,93)(H,81,94)(H,82,91)(H,97,98)/t49?,51?,60-,62-,64?,76-/m0/s1
InChIKey: ULRUOUDIQPERIJ-PQURJYPBSA-N

Cross-matching ID

PubChem CID: 91668186
UNII: M9BYU8XDQ6
DrugBank ID: DB12893
TTD ID: D8LAE2

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor associated calcium signal transducer 2 (TACSTD2)	TTP2HE5	TACD2_HUMAN	Not Available	[3]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website.
2	ClinicalTrials.gov (NCT05089734) Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy. U.S.National Institutes of Health.
3	Sacituzumab Govitecan: First Approval. Drugs. 2020 Jul;80(10):1019-1025.